All In Biotech

Investigational drug · Phase 2

BI 3812465

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabetic Macular Edema.

Phase 2

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "BI 3812465"

First trial start

2026

May 14, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "BI 3812465", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Diabetic Macular Edema

Approved drugs for the same conditions: Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "BI 3812465" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Diabetic Macular Edema

  • 4D-1503E10 vg, eyePhase 35 trials

    4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration

  • EYP-1901Phase 34 trials

    EyePoint Pharmaceuticals, Inc. · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)

  • OCS-01Phase 32 trials

    Oculis · Diabetic Macular Edema

  • AVT29proposed aflibercept HD biosimilarPhase 31 trial

    Alvotech Swiss AG · Diabetic Macular Edema

  • Roche (Genentech) · Diabetic Macular Edema

  • CU06-1004Phase 21 trial

    Curacle Co., Ltd. · DME, Diabetic Macular Edema, Diabetic Macular Edema (DME)

  • OXU-001DEXAspheresPhase 21 trial

    Oxular Limited · Diabetic Macular Edema

  • RO7446603Phase 21 trial

    Roche (Genentech) · Diabetic Macular Edema

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.